Table 4.

Ongoing and recently completed cooperative group clinical trials in elderly AML

Cooperative group	Study ID	Phase	Purpose	Status
ECOG	E2906	III	Evaluate Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)	Ongoing
ECOG	E3999	II	Evaluate Daunorubicin & Cytarabine +/− Zosuquidar in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia	Completed
SWOG	S0605	II	Evaluate Lenalidomide for Previously Untreated Non-M3, Deletion 5Q AML in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy	Ongoing, not recruiting
SWOG	S0703	II	Evaluate Azacitidine Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3	Ongoing, not recruiting
SWOG	S0301	II	Evaluate Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 AML In Patients Of Age 56 Or Older	Completed
Leukaemia Lymphoma Research and NCRI Working Group	Pick a Winner Program (LI-1)	II/III	Evaluate low dose cytarabine vs. sapacitabine vs. vosaroxin vs low dose cytarabine + vosaroxin vs. low dose cytarabine + AC220	Ongoing
MRC	AML 18 pilot	I/II	To Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220 or the CXCR4 Inhibitor Plerixafor or the HSP90 Inhibitor, Ganetespib, with Chemotherapy in Older Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome in Patients Over 60 Years	Ongoing

ECOG = Eastern Cooperative Oncology Group, SWOG = Southwest Oncology Group, NCRI = U.K. National Cancer Research Institute, MRC = Medical Research Council.